Results 231 to 240 of about 8,460,931 (324)

Microplastics as Emerging Neurotoxins: Brain Accumulation, Neuroinflammation, and Neurodegeneration Risk

open access: yesJournal of Biochemical and Molecular Toxicology, Volume 40, Issue 10, October 2026.
Microplastics and nanoplastics (MPs/NPs) are emerging environmental neurotoxicants capable of accumulating in the human brain through blood‐brain barrier transcytosis and olfactory transport pathways. Once within the central nervous system, MPs/NPs trigger interconnected mechanisms including NLRP3 inflammasome activation, oxidative stress ...
Alfi Sophian, Asmariani, Erika Ismayani
wiley   +1 more source

Gray Matter Microstructure Measured Using Diffusion Imaging as a Biomarker of Severity in Lewy Body Diseases. [PDF]

open access: yesMov Disord
Zarkali A   +9 more
europepmc   +1 more source

Harnessing Natural Killer Cells: From Neuroimmunology to Novel Therapies for Central Nervous System Diseases

open access: yesMedComm, Volume 7, Issue 10, October 2026.
This review delineates the multifaceted roles of natural killer (NK) cells in the central nervous system, spanning direct cytolysis, immunoregulation, and crosstalk with the brain microenvironment. We evaluate the translational potential and challenges of NK cell immunotherapies for a spectrum of neurological conditions.
Kaihang Deng, Wai Po Chong
wiley   +1 more source

Revisiting the Association of Pesticide Exposure and Parkinson's Disease: Systematic Review and Meta‐Analysis

open access: yesEnvironmental Toxicology, Volume 41, Issue 10, Page 875-888, October 2026.
ABSTRACT The association between pesticide exposure and Parkinson's disease (PD) is substantial, but heterogeneity in methodology and lack of categorization according to the type of exposure and pesticide classes in previous meta‐analyses impair the interpretation of data. This study aims to update evidence of the association between pesticide exposure
Pedro Henrique Passos da Silva   +6 more
wiley   +1 more source

Inhibition of Abnormal Elevated α‐Synuclein Ameliorates Dopaminergic Neuron Degeneration in Parkinson's Disease Mouse Model

open access: yesAging Cell, Volume 25, Issue 10, October 2026.
α‐Syn‐HDOs protect dopaminergic neurons by enhancing BDNF–TrkB signaling through the inhibition of abnormally elevated α‐Syn. These findings position α‐Syn‐HDOs as promising therapeutic candidates for PD and suggest that BDNF may serve as a potential diagnostic biomarker or indicator of treatment efficacy.
Xuenan Wang   +9 more
wiley   +1 more source

Mitochondrial Fusion and Fission in Age‐Related Cardio‐Cerebral Diseases: Mechanisms and Interventions

open access: yesAging Cell, Volume 25, Issue 10, October 2026.
Mitochondrial fission‐fusion imbalance contributes to age‐related cardio‐cerebral diseases like Alzheimer's disease, Parkinson's disease, Cerebral Infarction, Arteriosclerosis, Myocardial Infarction, Cardiac valve disease, Hypertension, and Cardiomyopathy. This review summarizes its regulatory mechanisms and interventions.
Yuyao Yin, Zijian Li
wiley   +1 more source

Associations Between Kidney Function and Risk of Cognitive Impairment Among Chinese Older Adults

open access: yesGeriatrics &Gerontology International, Volume 26, Issue 10, October 2026.
This graphical abstract illustrates the association between kidney function and risk of cognitive impairment among Chinese older adults from the CLHLS cohort. Reduced eGFR and elevated ACR assessed at baseline were significantly associated with higher odds of both prevalent and incident cognitive impairment, after adjusting for sociodemographic and ...
Xin Wang   +3 more
wiley   +1 more source

Targeting BPOZ-2 in Lewy body disease

open access: yesNeural Regeneration Research, 2016
Avik Roy
doaj   +1 more source

One of the Many Things That I've Learned on This Journey…: A Co‐operative, Narrative Inquiry With Two Care Partners of Spouses With Young Onset Dementia

open access: yesHealth Expectations, Volume 29, Issue 5, October 2026.
ABSTRACT Introduction Young‐onset dementia (YOD) is a term used when people demonstrate symptoms or are diagnosed with dementia before 65 years of age. YOD can be challenging to diagnose because health practitioners often do not initially consider dementia as the cause of someone's change in health or function in their 40 s, 50 s or even early 60 s ...
Elissa Burton   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy